Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Proven alternatives deliver comparable results with established safety: tirzepatide monotherapy produces 15-22% weight loss with FDA approval and extensive clinical data, while CagriSema (cagrilintide + semaglutide) delivers 15-25% weight loss with Phase 3 trial validation and clearer path to medical acceptance
Access to Beyond Whoosh depends on clinician review, location, pharmacy availability, and current compounding rules
P.AnandarajM
Reference Bowers, C
US$ 22.70
US$ 26.97
US$ 20.97
US$ 27.00
